Apogee Therapeutics, Inc.
APGE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APGE
Apogee Therapeutics is a clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology indications, with lead candidate zumilokibart (APG777) targeting atopic dermatitis and asthma.
Key risk: No revenue and reliance on funding
BioSniper Score
Based on 6 of 6 signals
Market Cap
$10.22B
Cash Runway
39.3 moLead Asset
apg273 (Preclinical)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 4 clinical trials · 3 catalysts for Apogee Therapeutics, Inc..
Apogee Therapeutics is a clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology indications, with lead candidate zumilokibart (APG777) targeting atopic dermatitis and asthma.
- Lead product candidate zumilokibart (APG777) is in Phase 2 trials for atopic dermatitis and asthma, with Phase 2 topline data expected by end of 2026 [sec_mda · as of 2026-08-10].
- Cash and equivalents were $105.6M as of 2026-06-30, with a net loss of -$85.9M for the period [sec].
- The company plans to initiate Phase 3 trials of zumilokibart in the second half of 2026, targeting a potential commercial launch in 2029 in what it believes could be a $50 billion AD market [sec · filed 2026-03-23].
- Additional pipeline programs include APG279 (IL-13 + OX40L) with a Phase 1b head-to-head trial vs. DUPIXENT for moderate-to-severe AD, with data readout expected 2H 2026 [sec · filed 2026-05-27].
- The company has not generated any revenue since inception and will need substantial additional funding to support continued operations [sec_mda · as of 2026-05-11].
What works
- Zumilokibart has a broad potential market opportunity in atopic dermatitis, which the company believes could be a $50 billion market [sec · filed 2026-03-23].
- The company has a clear clinical development timeline with multiple near-term data readouts, including Phase 2 topline data for zumilokibart and apg777 by end of 2026 [catalyst].
- Apogee is advancing a pipeline of novel biologics beyond zumilokibart, including APG279 and APG273, targeting multiple inflammatory indications [sec · filed 2026-05-27].
What to weigh
- The company has no approved products and has not generated any revenue since inception, relying entirely on external funding [sec_mda · as of 2026-05-11].
- Cash and equivalents of $105.6M as of 2026-06-30 may be insufficient to complete development and commercialization without additional financing [sec].
- The company faces significant clinical and regulatory risks common to early-stage biotech, including the need to obtain regulatory approval for its programs [sec_mda · as of 2026-03-02].
From the filings
Quoted directly from source documents.
The company plans to begin Phase 3 trials of zumilokibart in 2H 2026.
“the company plans to begin Phase 3 trials of zumilokibart in the second half of 2026 enabling a potential commercial launch in 2029”
SEC filings · March 23, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · zumilokibart — Phase 2 Readout: zumilokibart — Topline data from the Phase 2 trial of zumilokibart in atopic dermatitis or asthma will be reported.
- 2026-12-31 · Phase2_Topline · apg777 — Phase 2 Readout: apg777 — Topline data from the Phase 2 trial of apg777 will be reported.
- 2027-12-31 · Phase2_Topline · zumilokibart — Phase 2 Readout: zumilokibart — Additional Phase 2 readout for zumilokibart expected in 2027.
Risks & what to watch (3)›
Key risks
- No revenue and reliance on funding — The company has not generated any revenue since inception and will need substantial additional funding to support continued operations [sec_mda · as of 2026-05-11].
- Clinical and regulatory uncertainty
- Cash runway constraints — Cash of $105.6M as of 2026-06-30 may not be sufficient to complete development without additional capital [sec].
What to watch
- Phase 2 topline data for zumilokibart and apg777 expected by end of 2026 [catalyst].
- Initiation of Phase 3 trials for zumilokibart in 2H 2026 [sec · filed 2026-03-23].
- Phase 1b head-to-head data for APG279 vs. DUPIXENT expected 2H 2026 [sec · filed 2026-05-27].
- Announcement of further clinical plans for APG273 and additional pipeline program in 1H 2027 [sec · filed 2026-05-27].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Apogee Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apogee Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
39.3 months
OCF -$71M · Net income -$86M
Lead: Phase 2
5 candidates
3 upcoming, next in ~123d
0 buys · 35 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
228
Total value held
$5.67B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,262,291 | $779.6M |
| vanguard capital management llc | 5,004,190 | $421.2M |
| janus henderson group plc | 4,721,192 | $397.6M |
| wellington management group llp | 4,375,703 | $368.3M |
| blackrock, inc. | 4,085,651 | $343.9M |
| perceptive advisors llc | 3,080,768 | $259.3M |
| rtw investments, lp | 2,782,097 | $234.2M |
| state street corp | 2,162,964 | $182.1M |
| driehaus capital management llc | 1,920,800 | $161.7M |
| paradigm biocapital advisors lp | 1,348,243 | $113.5M |
Showing top 10 of 228 institutional holders of Apogee Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.9%
- Days to cover
- 13.6
- Shares short
- 9,489,537
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APGE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Apogee Therapeutics, Inc.?
Apogee Therapeutics is a clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology indications, with lead candidate zumilokibart (APG777) targeting atopic dermatitis and asthma.
What is Apogee Therapeutics, Inc.'s lead drug candidate?
Apogee Therapeutics, Inc.'s most advanced tracked candidate is apg273 (Preclinical) for asthma and COPD.
What is Apogee Therapeutics, Inc.'s next catalyst?
Apogee Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: zumilokibart" — expected December 31, 2026.
Who is the CEO of Apogee Therapeutics, Inc.?
Dr. Michael Thomas Henderson M.D. is the chief executive officer of Apogee Therapeutics, Inc. (APGE).
Where is Apogee Therapeutics, Inc. headquartered?
Apogee Therapeutics, Inc. (APGE) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.